Crinetics Pharmaceuticals (NASDAQ:CRNX) Lowered to Hold Rating by Piper Sandler

08 Jul 2026, 11:24 by Sarita Garza · The Markets Daily

Piper Sandler downgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) from a strong-buy rating to a hold rating in a research report report published on Tuesday morning,Zacks.com reports.

Several other research firms have also commented on CRNX. Citizens Jmp reiterated a “market outperform” rating and set a $95.00 price target on shares of Crinetics Pharmaceuticals in a report on Thursday, June 11th. UBS Group assumed coverage on shares of Crinetics Pharmaceuticals in a report on Thursday, July 2nd. They issued a “buy” rating and a $55.00 price objective for the company. Cantor Fitzgerald restated a “neutral” rating on shares of Crinetics Pharmaceuticals in a research report on Tuesday. Robert W. Baird lifted their target price on shares of Crinetics Pharmaceuticals from $62.00 to $85.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Wall Street Zen upgraded shares of Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 17th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $78.27.

Check Out Our Latest Analysis on CRNX

Crinetics Pharmaceuticals Price Performance

CRNX stock opened at $83.53 on Tuesday. The business has a 50 day simple moving average of $37.67 and a 200-day simple moving average of $41.76. The firm has a market capitalization of $8.81 billion, a PE ratio of -16.28 and a beta of 0.23. Crinetics Pharmaceuticals has a 1 year low of $25.83 and a 1 year high of $83.63.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.01). The company had revenue of $10.73 million for the quarter, compared to analysts’ expectations of $8.51 million. Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The business’s quarterly revenue was up 2873.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.04) EPS. On average, equities research analysts expect that Crinetics Pharmaceuticals will post -4.86 EPS for the current year.

Insider Activity at Crinetics Pharmaceuticals

In other news, Director Stephanie Okey sold 6,900 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the transaction, the director directly owned 6,400 shares in the company, valued at $228,288. This trade represents a 51.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the completion of the sale, the director directly owned 19,225 shares of the company’s stock, valued at $769,000. The trade was a 13.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its position in Crinetics Pharmaceuticals by 107.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock valued at $30,000 after acquiring an additional 331 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Crinetics Pharmaceuticals during the second quarter worth about $30,000. Raymond James Financial Inc. purchased a new position in shares of Crinetics Pharmaceuticals in the second quarter valued at approximately $45,000. Parallel Advisors LLC boosted its stake in shares of Crinetics Pharmaceuticals by 34.6% in the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock valued at $57,000 after purchasing an additional 315 shares during the period. Finally, Arax Advisory Partners grew its holdings in shares of Crinetics Pharmaceuticals by 131.2% in the fourth quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock valued at $70,000 after purchasing an additional 850 shares in the last quarter. 98.51% of the stock is currently owned by hedge funds and other institutional investors.

More Crinetics Pharmaceuticals News

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

Positive Sentiment: Vertex’s $85-per-share cash offer gives CRNX shareholders a sizable acquisition premium and effectively anchors the stock near the deal value. Article Title
Positive Sentiment: The acquisition validates Crinetics’ rare-disease pipeline, including PALSONIFY and Atumelnant, which were cited as key strategic assets in the transaction. Article Title
Neutral Sentiment: Multiple analysts have kept hold/neutral views or raised targets to the deal price, suggesting limited upside beyond the takeover value. Article Title
Negative Sentiment: Piper Sandler and Lifesci Capital downgraded Crinetics from strong buy to hold, which may temper enthusiasm after the rally. Article Title
Negative Sentiment: Recent insider selling and unusual put option activity could signal some caution around the stock’s near-term trading. Article Title

Crinetics Pharmaceuticals Company Profile

(Get Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.